Fidanacogene elaparvovec, sold under the brand name Beqvez among others, is a gene therapy delivered via adeno-associated virus used for the treatment of ...

26 апр. 2024 г. · U.S. FDA Approves Pfizer's BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B · Currently use factor ...

25 сент. 2024 г. · Fidanacogene elaparvovec is an AAV vector that is designed to deliver transgene production of FIX-R338L for hemophilia B. The transgene ...

20 мая 2024 г. · Fidanacogene elaparvovec-dzkt. Tradename: BEQVEZ Manufacturer: Pfizer, Inc. Indication: For the treatment of adults with moderate to severe ...

BEQVEZ™ is a one-time gene therapy infusion used to treat moderate to severe hemophilia B in eligible adult male patients. See risks & important safety ...

6 мая 2024 г. · Для чего используется этот лекарственный препарат? Он используется для лечения некоторых людей с гемофилией B. Что необходимо сообщить врачу ...

26 сент. 2024 г. · Fidanacogene elaparvovec was superior to prophylaxis for the treatment of participants with hemophilia B, leading to reduced bleeding and ...

31 мая 2024 г. · The active substance in Durveqtix, fidanacogene elaparvovec, is based on a virus that has been modified to contain a copy of the gene ... Overview · Product information · Authorisation details

27 июн. 2023 г. · Fidanacogene elaparvovec is a novel, investigational gene therapy that contains a bio-engineered AAV capsid and a high-activity variant of human ...

Fidanacogene elaparvovec is an AAV vector-based gene therapy indicated for the treatment of adults (aged 18 years or older) with moderately severe to severe ...